|1.||Fogari, Roberto: 9 articles (01/2011 - 07/2003)|
|2.||Mugellini, Amedeo: 7 articles (01/2011 - 07/2003)|
|3.||Cremonesi, Giovanni: 6 articles (01/2012 - 05/2003)|
|4.||Zoppi, Annalisa: 5 articles (01/2008 - 07/2003)|
|5.||Preti, Paola: 3 articles (01/2008 - 07/2003)|
|6.||Rinaldi, Andrea: 3 articles (01/2008 - 07/2003)|
|7.||Zalvidea, S: 2 articles (01/2015 - 02/2012)|
|8.||Thireau, J: 2 articles (01/2015 - 02/2012)|
|9.||Richard, S: 2 articles (01/2015 - 02/2012)|
|10.||Aimond, F: 2 articles (01/2015 - 02/2012)|
|1.||Hypertension (High Blood Pressure)
01/01/1991 - "Delapril effectively lowered blood pressure in 73% of 1,008 patients with hypertension during clinical trials in Japan. "
05/01/2006 - "After a 2-wk placebo period, 303 patients with mild to moderate essential hypertension were randomized in a double-blind study to 8 wk of treatment with placebo, or delapril 7.5 mg twice daily, delapril 15 mg twice daily, delapril 30 mg twice daily, or delapril 30 mg once daily. "
09/01/1995 - "Patients with mild to moderate essential hypertension were treated mainly with an ACE inhibitor (delapril, n = 980) or a Ca antagonist (n = 956) for 12 months, and the incidence of cerebrovascular and cardiovascular events as well as drug-related side effects were compared between the two groups. "
06/16/1995 - "At doses ranging from 1-10 mg/kg orally, delapril exerts a marked and long-lasting antihypertensive action in various experimental models of hypertension. "
01/01/1987 - "Thus delapril may represent a useful antihypertensive agent for control of blood pressure in patients with essential hypertension."
06/16/1995 - "Multicenter, randomized, placebo-controlled, double-blind study of the safety and efficacy of oral delapril in patients with congestive heart failure."
06/16/1995 - "A total of 101 patients (67 delapril, 34 placebo) with congestive heart failure, New York Heart Association (NYHA) classes II and III, entered a multicenter, randomized (2:1), double-blind, placebo-controlled study to determine the minimum effective and maximum tolerated doses of delapril. "
02/01/2012 - "We investigated the effects of the ACE-I delapril on cardiomyocytes in a mouse model of heart failure (HF) after MI. "
09/01/1999 - "In conclusion, 1 month of treatment with doses of delapril having no hemodynamic effect, reduced LV volume in a model of chronic heart failure. "
06/16/1995 - "To evaluate the safety and efficacy of delapril versus enalapril in patients with congestive heart failure (CHF), New York Heart Association (NYHA) class II and III, 198 patients were enrolled in a study in 13 centers involving a double-blind parallel group design. "
01/01/1995 - "Effects of delapril on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats."
11/01/1998 - "Protective effects of delapril, indapamide and their combination on stroke occurrence and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats."
01/01/2007 - "Furthermore, combining an ACE inhibitor and a thiazide-type diuretic has been associated with a decreased risk of stroke and is recommended for patients with cerebrovascular disease, a setting in which the combination of delapril and indapamide has therapeutic potential. "
01/01/1995 - "These results indicate that delapril can prevent the development of symptoms of hypertensive cardiovascular diseases: stroke, kidney dysfunction and cardiac hypertrophy, with antihypertensive activity in SHRSP."
11/01/1998 - "The effects of long-term oral administration of delapril (CAS 83435-67-0), indapamide (CAS 26807-65-8) and their combination on the occurrence of stroke and on mortality were investigated in young salt-loaded stroke-prone spontaneously hypertensive rats (SHRsp) for 31 weeks of treatment (8th-39th week of age) and up to 8 weeks thereafter. "
06/01/1995 - "TCV-116 and delapril each significantly attenuated the increases in left ventricular end diastolic pressure, left ventricular weight, right ventricular weight, and LVEDVI following myocardial infarction in both in WKY and SHR, and shifted pressure-volume curve significantly to the left. "
03/01/2013 - "Moreover, the benefits of delapril are not limited to hypertensive patients, but also in those with microalbuminuria, left ventricular hypertrophy, myocardial infarction or heart failure; delapril appears to be effective and well tolerated."
07/01/2003 - "Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial."
09/01/1999 - "Because ACE inhibition is a recommended treatment for heart failure, this study was designed to test the effects on neurohumoral activation, hemodynamics, and left ventricular (LV) volume of the combination of an ACE inhibitor (delapril) with a DA2-dopaminergic receptor/alpha2-adrenoceptor agonist (CHF-1024) or a beta1-adrenoceptor antagonist (metoprolol) after a moderate to large myocardial infarction (MI) in rats. "
06/01/1995 - "The aims were (1) to investigate the effect of hypertention on left ventricular dilatation and haemodynamic alterations following acute myocardial infarction in spontaneously hypertensive rats (SHR) and normotensive rats (WKY); (2) to compare haemodynamic indices between the two groups; (3) to assess whether the angiotensin II type 1 receptor antagonist (AIIA), TCV-116, prevented left ventricular dilatation after myocardial infarction; and (4) to compare the effect of AIIA with that of the angiotensin converting enzyme (ACE) inhibitor, delapril. "
10/01/2012 - "We longitudinally studied 600 hypertensive type 2 diabetic patients with albuminuria <200 μg/min and who were retrieved from two randomized trials testing the renal effect of trandolapril and delapril. "
02/01/2000 - "The risk of progression to overt albuminuria was significantly different between manidipine and delapril groups (P = 0.011). "
02/01/2000 - "Overt albuminuria developed in four patients on manidipine but did not appear in any of the patients on delapril. "
02/01/2000 - "In conclusion, delapril was significantly more effective than manidipine in inhibiting progression to overt albuminuria in hypertensive type 2 diabetes mellitus patients."
06/01/1993 - "Although TCV-116, delapril, and hydralazine treatment significantly improved the survival rate for 4 weeks, hydralazine failed to improve proteinuria and albuminuria as well as the decline in renal function compared with delapril or TCV-116. "
|5.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|9.||candesartan cilexetil (Amias)
|3.||Surgical Instruments (Clip)